| Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma | |
| Shi, Yuan-Kai; Dong, Mei; Hong, Xiao-Nan; Zhang, Wei-Jing; Feng, Ji-Feng; Zhu, Jun; Yu, Li; Ke, Xiao-Yan; Huang, Hui-Qiang; Shen, Zhi-Xiang | |
| 2013 | |
| 会议名称 | JOURNAL OF CLINICAL ONCOLOGY |
| 会议日期 | 2013-05-20 |
| 收录类别 | CPCI-S |
| URL标识 | 查看原文 |
| 内容类型 | 会议论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/6696409 |
| 专题 | 中国医学科学院 北京协和医学院 |
| 推荐引用方式 GB/T 7714 | Shi, Yuan-Kai,Dong, Mei,Hong, Xiao-Nan,et al. Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma[C]. 见:JOURNAL OF CLINICAL ONCOLOGY. 2013-05-20. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论